Jefferies Financial Group Analysts Cut Earnings Estimates for Osmotica Pharmaceuticals PLC (NASDAQ:OSMT)

Osmotica Pharmaceuticals PLC (NASDAQ:OSMT) – Stock analysts at Jefferies Financial Group reduced their FY2020 earnings estimates for Osmotica Pharmaceuticals in a research note issued on Monday, August 12th. Jefferies Financial Group analyst D. Steinberg now forecasts that the company will earn ($0.18) per share for the year, down from their previous estimate of ($0.17). Jefferies Financial Group currently has a “Buy” rating and a $10.00 price target on the stock. Jefferies Financial Group also issued estimates for Osmotica Pharmaceuticals’ FY2022 earnings at $0.94 EPS and FY2023 earnings at $1.75 EPS.

Osmotica Pharmaceuticals (NASDAQ:OSMT) last issued its quarterly earnings data on Thursday, August 8th. The company reported $0.02 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.04) by $0.06. The company had revenue of $57.53 million for the quarter, compared to analyst estimates of $57.90 million.

Several other research analysts also recently issued reports on the company. Barclays began coverage on Osmotica Pharmaceuticals in a research report on Tuesday, June 11th. They set an “overweight” rating and a $11.00 price objective for the company. Zacks Investment Research upgraded Osmotica Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, July 16th. Wells Fargo & Co reiterated a “buy” rating on shares of Osmotica Pharmaceuticals in a report on Friday, August 9th. Finally, ValuEngine upgraded Osmotica Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $13.00.

Shares of Osmotica Pharmaceuticals stock opened at $2.89 on Thursday. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.70 and a quick ratio of 1.41. Osmotica Pharmaceuticals has a 1 year low of $2.20 and a 1 year high of $9.90. The company has a market capitalization of $148.90 million and a P/E ratio of -5.67. The business has a 50 day moving average price of $3.47 and a 200 day moving average price of $4.46.

A number of institutional investors and hedge funds have recently modified their holdings of OSMT. SG Americas Securities LLC acquired a new position in Osmotica Pharmaceuticals in the 1st quarter valued at $45,000. Deutsche Bank AG acquired a new position in Osmotica Pharmaceuticals in the 4th quarter valued at $111,000. Citadel Advisors LLC acquired a new position in Osmotica Pharmaceuticals in the 2nd quarter valued at $120,000. Jacobs Levy Equity Management Inc. acquired a new position in Osmotica Pharmaceuticals in the 2nd quarter valued at $142,000. Finally, Acadian Asset Management LLC raised its holdings in Osmotica Pharmaceuticals by 277.5% in the 2nd quarter. Acadian Asset Management LLC now owns 53,846 shares of the company’s stock valued at $206,000 after acquiring an additional 39,584 shares during the last quarter. Institutional investors own 11.66% of the company’s stock.

Osmotica Pharmaceuticals Company Profile

Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, develops, manufactures, and commercializes specialty products that target markets with underserved patient populations. The company's promoted approved products include specialty neurology products, such as M-72 to treat ADHD; Osmolex ER for treating Parkinson's and drug-induced extrapyramidal reactions in adults; Lorzone for muscle spasms; ConZip to treat pain; and Ontinua ER for treating opioid withdrawal symptoms.

Recommended Story: The primary rules of Elliott Wave theory

Receive News & Ratings for Osmotica Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Osmotica Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.